Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Global University Venturing

C4 Therapeutics seals $170m round

The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.


Jun 17, 2020

Goel moves into UToronto’s Covid-19 response

Vivek Goel will move into a coronavirus response-oriented advisory role having been University of Toronto vice-president for research, innovation and strategic initiatives since 2015.

Jun 17, 2020

Wandelbots wins $30m

Wandelbots, which came out of Technical University of Dresden research, secured the funding as it publicly launched its robotics training software tool.

Jun 17, 2020

Daily deal net: June 17, 2020

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Jun 17, 2020

4DMT materialises $75m series C round

4D Molecular Therapeutics secured the return of Berkeley Catalyst Fund for a series C round that follows plans for a $100m IPO announced in September 2019.

Jun 17, 2020

CureVac gets a $339m kick from KfW

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

Jun 16, 2020

Daily deal net: June 16, 2020

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Jun 16, 2020

Immvira reveals $58m series B round

Based on research from academic schools including Princeton, Chicago and Alabama at Birmingham, the oncolytic viral therapy developer has now received more than $80m to date.

Jun 16, 2020

Kahoot cajoles $28m in private placement

The educational game portal, a spinout of Norwegian University of Science and Technology, pulled in $28m as investors also bought $62m of secondary shares.

Jun 16, 2020

Verve swerves into $63m

GV, a corporate venturing subsidiary of internet and technology group Alphabet, has led a $63m series A2 round for Verve Therapeutics, a US-based developer of genomic heart disease drugs.

Jun 15, 2020

Bit Bio whips up series A funding

University of Cambridge stem cell differentiation spinout Bit Bio secured $41.5m from investors including Arch Venture Partners to boost its overall funding to $50m.

Jun 15, 2020

IQM Finland inspects $16.9m

The Aalto University and VTT quantum computer spinout has lined up a potential series A round with an initial $16.9m contribution from EIC Accelerator.

Jun 15, 2020
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here